(VTRS) Viatris - Ratings and Ratios
Generic Drugs, Biosimilars, Prescription Brand Drugs, Complex Dosage Forms
VTRS EPS (Earnings per Share)
VTRS Revenue
Description: VTRS Viatris
Viatris Inc. is a global healthcare company operating across multiple regions, including North America, Europe, and Asia, with a diverse portfolio of pharmaceutical products. The company operates through four main segments: Developed Markets, Greater China, JANZ, and Emerging Markets, offering a range of prescription brand drugs, generic drugs, complex generic drugs, and biosimilars.
The companys product portfolio covers various therapeutic areas, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, and oncology, among others. Viatris also provides support services, such as diagnostic clinics and digital tools, to help patients manage their health. The companys products are distributed through various channels, including pharmaceutical wholesalers, retailers, and specialty pharmacies.
From a financial perspective, Viatris has a market capitalization of approximately $10.4 billion. The companys forward P/E ratio is around 4.06, indicating a relatively low valuation compared to its expected earnings. However, the Return on Equity (RoE) is negative at -20.60%, suggesting that the company is currently facing challenges in generating profits for its shareholders.
Some key performance indicators (KPIs) to monitor for Viatris include revenue growth, gross margin, and operating cash flow. The companys ability to successfully integrate its products and services, as well as its collaborations with other pharmaceutical companies, such as Mapi Pharma Ltd. and Revance Therapeutics, Inc., will be crucial in driving future growth. Additionally, the companys pipeline of biosimilars and complex generics could provide opportunities for expansion. Key metrics to track include the companys progress in developing and commercializing new products, as well as its ability to manage costs and improve profitability.
To further analyze Viatris, it would be essential to examine its financial statements, including the income statement, balance sheet, and cash flow statement, to gain insights into its revenue streams, debt levels, and cash generation capabilities. Moreover, monitoring industry trends, competitor activity, and regulatory developments will be crucial in understanding the companys prospects and potential risks.
VTRS Stock Overview
| Market Cap in USD | 12,300m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2020-11-16 |
VTRS Stock Ratings
| Growth Rating | -24.3% |
| Fundamental | 27.8% |
| Dividend Rating | 59.4% |
| Return 12m vs S&P 500 | -28.3% |
| Analyst Rating | 3.44 of 5 |
VTRS Dividends
| Dividend Yield 12m | 4.72% |
| Yield on Cost 5y | 3.68% |
| Annual Growth 5y | 9.82% |
| Payout Consistency | 57.2% |
| Payout Ratio | 19.9% |
VTRS Growth Ratios
| Growth Correlation 3m | 75.7% |
| Growth Correlation 12m | -65.1% |
| Growth Correlation 5y | -44.4% |
| CAGR 5y | 5.88% |
| CAGR/Max DD 3y | 0.13 |
| CAGR/Mean DD 3y | 0.40 |
| Sharpe Ratio 12m | -0.11 |
| Alpha | -27.45 |
| Beta | 0.727 |
| Volatility | 29.13% |
| Current Volume | 17794.7k |
| Average Volume 20d | 7589k |
| Stop Loss | 9.3 (-3.1%) |
| Signal | -2.27 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-3.47b TTM) > 0 and > 6% of Revenue (6% = 846.1m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 57.39% (prev 26.81%; Δ 30.58pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 2.06b > Net Income -3.47b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.17b) change vs 12m ago -1.52% (target <= -2.0% for YES) |
| Gross Margin 36.73% (prev 41.37%; Δ -4.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.68% (prev 33.59%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.53 (EBITDA TTM -490.9m / Interest Expense TTM 497.9m) >= 6 (WARN >= 3) |
Altman Z'' 0.87
| (A) 0.21 = (Total Current Assets 9.77b - Total Current Liabilities 1.68b) / Total Assets 38.41b |
| (B) 0.00 = Retained Earnings (Balance) 80.0m / Total Assets 38.41b |
| (C) -0.08 = EBIT TTM -3.25b / Avg Total Assets 41.87b |
| (D) 0.00 = Book Value of Equity 80.0m / Total Liabilities 22.84b |
| Total Rating: 0.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.79
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield 6.50% = 3.25 |
| 3. FCF Margin 12.09% = 3.02 |
| 4. Debt/Equity 0.93 = 2.09 |
| 5. Debt/Ebitda -29.48 = -2.50 |
| 6. ROIC - WACC -14.49% = -12.50 |
| 7. RoE -19.92% = -2.50 |
| 8. Rev. Trend -79.53% = -5.97 |
| 9. EPS Trend -72.07% = -3.60 |
What is the price of VTRS shares?
Over the past week, the price has changed by -8.40%, over one month by -8.49%, over three months by +8.00% and over the past year by -14.79%.
Is Viatris a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VTRS is around 9.91 USD . This means that VTRS is currently overvalued and has a potential downside of 3.23%.
Is VTRS a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the VTRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 11.4 | 19.1% |
| Analysts Target Price | 11.4 | 19.1% |
| ValueRay Target Price | 10.6 | 10.8% |
Last update: 2025-09-05 05:07
VTRS Fundamental Data Overview
CCE Cash And Equivalents = 566.4m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 4.3592
P/S = 0.8714
P/B = 0.79
P/EG = 0.0728
Beta = 0.897
Revenue TTM = 14.10b USD
EBIT TTM = -3.25b USD
EBITDA TTM = -490.9m USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 1.68b USD (from shortTermDebt, last quarter)
Debt = 14.47b USD (Calculated: Short Term 1.68b + Long Term 12.79b)
Net Debt = 13.91b USD (from netDebt column, last quarter)
Enterprise Value = 26.21b USD (12.30b + Debt 14.47b - CCE 566.4m)
Interest Coverage Ratio = -6.53 (Ebit TTM -3.25b / Interest Expense TTM 497.9m)
FCF Yield = 6.50% (FCF TTM 1.70b / Enterprise Value 26.21b)
FCF Margin = 12.09% (FCF TTM 1.70b / Revenue TTM 14.10b)
Net Margin = -24.59% (Net Income TTM -3.47b / Revenue TTM 14.10b)
Gross Margin = 36.73% ((Revenue TTM 14.10b - Cost of Revenue TTM 8.92b) / Revenue TTM)
Tobins Q-Ratio = 327.6 (set to none) (Enterprise Value 26.21b / Book Value Of Equity 80.0m)
Interest Expense / Debt = 0.81% (Interest Expense 116.6m / Debt 14.47b)
Taxrate = 21.0% (US default)
NOPAT = -3.25b (EBIT -3.25b, no tax applied on loss)
Current Ratio = 5.82 (Total Current Assets 9.77b / Total Current Liabilities 1.68b)
Debt / Equity = 0.93 (Debt 14.47b / last Quarter total Stockholder Equity 15.57b)
Debt / EBITDA = -29.48 (Net Debt 13.91b / EBITDA -490.9m)
Debt / FCF = 8.49 (Debt 14.47b / FCF TTM 1.70b)
Total Stockholder Equity = 17.41b (last 4 quarters mean)
RoA = -9.03% (Net Income -3.47b, Total Assets 38.41b )
RoE = -19.92% (Net Income TTM -3.47b / Total Stockholder Equity 17.41b)
RoCE = -10.76% (Ebit -3.25b / (Equity 17.41b + L.T.Debt 12.79b))
RoIC = -10.15% (NOPAT -3.25b / Invested Capital 32.02b)
WACC = 4.34% (E(12.30b)/V(26.77b) * Re(8.69%)) + (D(14.47b)/V(26.77b) * Rd(0.81%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -66.67 | Cagr: -0.34%
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 74.72% ; FCFE base≈1.78b ; Y1≈1.65b ; Y5≈1.51b
Fair Price DCF = 20.66 (DCF Value 24.09b / Shares Outstanding 1.17b; 5y FCF grow -9.15% → 3.0% )
EPS Correlation: -72.07 | EPS CAGR: -11.59% | SUE: 1.91 | # QB: True
Revenue Correlation: -79.53 | Revenue CAGR: -4.61%
Additional Sources for VTRS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle